Ischemic Heart Disease Clinical Trial
— rEPIC04AOfficial title:
Xperience Pro Post-Market Clinical Follow-up Study
Verified date | May 2023 |
Source | Fundación EPIC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Xperience Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Xperience Pro .
Status | Completed |
Enrollment | 46 |
Est. completion date | May 5, 2023 |
Est. primary completion date | April 26, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient treated with Xperience pro according to routine hospital practice and following instructions for use - Informed consent signed Exclusion Criteria: - Not meet inclusion criteria |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital Universitario de Getafe | Getafe | |
Spain | Hospital Universitario 12 de Octubre | Madrid | |
Spain | Hospital Universitario Marques de Valdecilla | Santander | |
Spain | Hospital Universitario Virgen de Valme | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Fundación EPIC |
Spain,
Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet. 1978 Feb 4;1(8058):263. doi: 10.1016/s0140-6736(78)90500-7. No abstract available. — View Citation
Kandzari DE, Teirstein PS, Kereiakes DJ, Cannon LA, Hearne SE, Kuo HC, Ying SW, Cheong WF, Popma JJ. Procedural effectiveness of a novel 1.20 mm diameter angioplasty catheter: clinical and angiographic outcomes. J Interv Cardiol. 2013 Apr;26(2):131-6. doi: 10.1111/j.1540-8183.2013.12021.x. Epub 2013 Jan 31. — View Citation
Kandzari DE, Zankar AA, Teirstein PS, Brilakis ES, Banerjee S, Price MJ, Stinis CT, Hudson PA, Dahle TG, Eng M, Brown R, Ferguson A, Addo TA, Popma JJ. Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter. Catheter Cardiovasc Interv. 2011 Mar 1;77(4):510-4. doi: 10.1002/ccd.22734. Epub 2010 Nov 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety Endpoint. Freedom from Target Lesion Failure | Freedom from TARGET LESION FAILURE (TLF), composite endpoint of cardiac death, myocardial infarction and and new Target Lesion Revascularization (TLR) | 7 days | |
Secondary | Efficacy Endpoint. Freedom from Target Lesion Failure | Freedom from TARGET LESION FAILURE (TLF), composite endpoint of cardiac death, myocardial infarction (MI) and and new Target Lesion Revascularization (TLR). | 7 days | |
Secondary | Freedom from Balloon rupture | Freedom from Balloon rupture | During percutaneous coronary intervention (PCI) | |
Secondary | Freedom from Hypotube rupture | Freedom from Hypotube rupture | During PCI | |
Secondary | Freedom from Complicated withdrawal | Freedom from Complicated withdrawal | During PCI | |
Secondary | Freedom from Coronary perforation | Freedom from Coronary perforation | During PCI | |
Secondary | Freedom from Coronary dissection >C | Freedom from Coronary dissection >C | During PCI | |
Secondary | Freedom from No reflow | Freedom from No reflow | During PCI | |
Secondary | Freedom from Coronary thrombosis | Freedom from Coronary thrombosis | During PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |